# A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

> **NCT06421298** · PHASE2 · RECRUITING · sponsor: **Jinghui Wang** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Tafolecimab
- **DRUG:** Sintilimab
- **DRUG:** Nab paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06421298
- **Lead sponsor:** Jinghui Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421298, "A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06421298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*